Residential College | false |
Status | 已發表Published |
2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy | |
Yingjun Peng1; Shengyu Fu1 | |
2022-05-26 | |
Source Publication | Journal of Leukocyte Biology |
ISSN | 0741-5400 |
Volume | 112Issue:4Pages:823-834 |
Abstract | Diverse cytokines and their receptors on immune cells constitute a highly complex network in the immune system. Some therapeutic cytokines and their derivatives have been approved for cancer treatment. IL-15 is an immune-regulating cytokine with multiple functions, among which the function of activating the immunity of cancer patients has great potential in cancer immunotherapy. In this review, we introduce the functions of IL-15 and discuss its role in regulating the immune system in different immune cells. Meanwhile, we will address the applications of IL-15 agonists in cancer immunotherapy and provide prospects for the next generation of therapeutic designs. Although many challenges remain, IL-15 agonists offer a new therapeutic option in the future direction of cancer immunotherapy. |
Keyword | Cytokine Il-15 Il-2 Immunotherapy Protein Engineering |
DOI | 10.1002/JLB.5MR0422-506R |
URL | View the original |
Indexed By | SCIE |
Language | 英語English |
WOS Research Area | Cell Biology ; Hematology ; Immunology |
WOS Subject | Cell Biology ; Hematology ; Immunology |
WOS ID | WOS:000803428800001 |
Publisher | WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ |
Scopus ID | 2-s2.0-85130616444 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | University of Macau |
Affiliation | 1.Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macao 2.MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macao |
First Author Affilication | Cancer Centre |
Recommended Citation GB/T 7714 | Yingjun Peng,Shengyu Fu. 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy[J]. Journal of Leukocyte Biology, 2022, 112(4), 823-834. |
APA | Yingjun Peng., & Shengyu Fu (2022). 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy. Journal of Leukocyte Biology, 112(4), 823-834. |
MLA | Yingjun Peng,et al."2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy".Journal of Leukocyte Biology 112.4(2022):823-834. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment